Ginkgo Bioworks Holdings (DNA) Accounts Payables (2020 - 2026)
Ginkgo Bioworks Holdings' (DNA) quarterly Accounts Payables came in at $16.3 million in Q1 2026, up 44.75% YoY from $11.3 million in Q1 2025, and up 54.35% on a QoQ basis from $10.6 million in Q4 2025.
Ginkgo Bioworks Holdings (DNA) Accounts Payables (2020 - 2026) Analysis & Trends
Ginkgo Bioworks Holdings (DNA) has 7 years of Accounts Payables data on file, last reported at $16.3 million in Q1 2026.
- Quarterly Accounts Payables rose 44.75% year-over-year to $16.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $16.3 million (up 44.75% YoY) and the FY2025 annual result came in at $10.6 million, down 25.43% from the prior year.
- Accounts Payables grew to $16.3 million in Q1 2026, from $10.6 million in the prior quarter.
- In the past five years, Accounts Payables ranged from a high of $35.3 million in Q1 2022 to a low of $9.3 million in Q4 2023.
- A 5-year average of $16.0 million and a median of $13.6 million in 2023 frame the typical range for Accounts Payables.
- Annual changes were most pronounced in 2022 — Accounts Payables surged 2379.71% — and 2025, when it plunged 58.26%.
- Tracing DNA's Accounts Payables over 5 years: stood at $10.5 million in 2022, then dropped by 10.79% to $9.3 million in 2023, then soared by 51.98% to $14.2 million in 2024, then fell by 25.43% to $10.6 million in 2025, then surged by 54.35% to $16.3 million in 2026.
- The last three Accounts Payables figures came in at $16.3 million (Q1 2026), $10.6 million (Q4 2025), and $10.7 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Accounts Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.52 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 88.42 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 470.30 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3.05 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 35.57 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 108.02 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 428.93 Mn |
| 10 | Ginkgo Bioworks Holdings | 432.60 Mn | 348.06 Mn | 18.44 Mn | 9.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 9.58 Mn |
| Mar 31, 2026 | 16.31 Mn |
| Dec 31, 2025 | 10.57 Mn |
| Sep 30, 2025 | 10.70 Mn |
| Jun 30, 2025 | 11.20 Mn |
| Mar 31, 2025 | 11.27 Mn |
| Dec 31, 2024 | 14.17 Mn |
| Sep 30, 2024 | 15.70 Mn |
| Jun 30, 2024 | 23.03 Mn |
| Mar 31, 2024 | 27.00 Mn |
| Dec 31, 2023 | 9.32 Mn |
| Sep 30, 2023 | 10.75 Mn |
| Jun 30, 2023 | 13.63 Mn |
| Mar 31, 2023 | 21.57 Mn |
| Dec 31, 2022 | 10.45 Mn |
| Sep 30, 2022 | 11.32 Mn |
| Jun 30, 2022 | 19.46 Mn |
| Mar 31, 2022 | 35.26 Mn |
| Dec 31, 2021 | 8.19 Mn |
| Sep 30, 2021 | 7.10 Mn |